Business Wire

BUREAU-VERITAS

4.4.2024 20:24:29 CEST | Business Wire | Press release

Share
Bureau Veritas Undertakes a Buyback of c.0.8% of Its Shares Under the Accelerated Placement Announced by Wendel

Bureau Veritas, a global leader in the Testing, Inspection and Certification (TIC) industry, today announces its decision to acquire from Wendel a block of its own shares – which will amount to a maximum of EUR 100 million and represent circa 0.8% of its capital. This buyback is carried out by way of participation in the accelerated bookbuilding process to institutional investors, including Lac1, managed by Bpifrance, as announced by Wendel today. The transaction has been approved unanimously by the independent directors.

Wendel remains Bureau Veritas’ largest shareholder after the completion of this transaction, with c.26% of the share capital and c.41% of the voting rights. Lac1, managed by Bpifrance, will become a new cornerstone investor with c.4% of the share capital.

IMPLEMENTATION OF A BUYBACK BY THE COMPANY OF 0.8% OF ITS OWN SHARES

Following today's announcement by Wendel of its intention to sell c.18 million Bureau Veritas shares representing approximately 9% of the share capital - a total consideration amount of up to EUR 1.1 billion - by way of an accelerated bookbuilding process, Bureau Veritas announces that it has undertaken to participate by placing an irrevocable purchase order, at the placement price, for its own shares (representing approximately 0.8% of its share capital) for a maximum total amount of EUR 100 million. This order is part of the share buyback program authorized by Bureau Veritas shareholders at the Annual General Meeting of June 22, 2023, and which the Board of Directors decided to implement at its meeting of April 3, 2024.

The share buyback price will be equal to the price resulting from the placement procedure and the building of the order book. The Company will not participate in the determination of the price resulting from the order book.

With this buyback, the Company is making significant progress on its objective, announced at the time of the presentation of its strategic plan on March 20, 2024, of purchasing its own shares under the buyback program for a maximum amount of EUR 200 million in 2024. This buyback will accelerate the objective of improving returns to shareholders by increasing earnings per share.

The buyback will be financed in cash from the Group's available cash, and will not affect the Company's ability to implement the announced strategic plan, or its development and financing capacities.

In accordance with the purpose of the share buyback program approved by the Annual General Meeting, the shares bought back will be used for cancellation purposes and for any other purposes authorized by the Company’s shareholders at the Annual General Meeting of June 22, 2023.

ACQUISITION OF A STAKE IN THE COMPANY BY LAC1, MANAGED BY BPIFRANCE

Lac1, managed by Bpifrance, has announced its intention to acquire a c.4% stake in the Company's capital as part of the disposal transaction initiated by Wendel.

On April 3, 2024, the Board of Directors has authorized the execution of an agreement to be entered into between Lac1, managed by Bpifrance, and the Company, pursuant to which it will be agreed that following Lac1’s acquisition of a stake in the Company, the Board of Directors will propose the appointment of Bpifrance as an independent director at the Board of Directors of Bureau Veritas in compliance with the parity rules or, if such an appointment cannot be made immediately, as an observer.

Hinda Gharbi, Chief Executive Officer of Bureau Veritas, commented: “The transaction demonstrates both our strong confidence in Bureau Veritas’ growth potential and our commitment to increasing shareholder returns as presented during our Capital Markets Day held on March 20th, 2024. I thank Wendel for their continuous and active support, and I am delighted to welcome Lac1, managed by Bpifrance, a strong French institutional investor, as a new significant shareholder of Bureau Veritas and a member of the Company’s board of directors.”

About Bureau Veritas

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress.

With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit www.bureauveritas.com, and follow us on X/Twitter (@bureauveritas) and LinkedIn.

Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404643494/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pythia Labs Launches with AI-Designed Antibodies for Hard-to-Drug Targets27.10.2026 13:00:00 CET | Press release

Biotech startup demonstrates rapid AI design of full-length human antibodies that inhibit or activate GPCRs, with key properties required for therapeutic development Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027891477/en/ Pythia's AI technology platform can design antibodies against traditionally challenging targets such as multi-pass membrane proteins. Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating antibodies that activate these receptors has been a longstanding goal in antibody discovery. Pythia-1 reasons jointly ov

Robbyant’s Inaugural Embodied AI Challenge Draws Over 1,800 Teams Ahead of Real-Robot Final in Shanghai27.10.2026 12:00:00 CET | Press release

Qualifier submissions for the inaugural Robbyant Embodied AI Challenge officially closed on October 27, marking the end of the competition’s online preliminary round. Organized by Robbyant, an embodied AI company within Ant Group, the challenge was launched in September at the 2026 Inclusion Conference on the Bund in partnership with ModelScope and Alibaba Cloud Tianchi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027768483/en/ The competition is based on the open-source LingBot-VLA 2.0 embodied foundation model and is designed for developers working on embodied AI algorithms. Participants are evaluated on model training and fine-tuning, simulation-based generalization, and adaptation to real robots. The challenge is open to enterprises, universities, individual developers and technology enthusiasts worldwide. More than 1,800 teams and thousands of developers from 13 countries have registered for the challenge. Partici

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 202627.10.2026 11:30:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available at the following link: https://lifescievents.com/event/csy40je/. The webcast will be archived for 30 days. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumati

Fortegra Appoints Guy House as SVP, Treaty Reinsurance27.10.2026 10:00:00 CET | Press release

The Fortegra Group, Inc. ("Fortegra" or the "Company"), a global specialty insurer and part of DB Insurance Co., Ltd., has appointed Guy House as Senior Vice President, Treaty Reinsurance. In this role, he will lead Fortegra’s treaty reinsurance underwriting strategy from the Company’s UK office. Mr. House brings more than 18 years of London market experience. He has written and bought reinsurance across multiple product lines and tiers, including property, marine, energy, terrorism and aviation. His expertise spans treaty and retrocession reinsurance, direct and facultative (D&F) insurance, exposure management, alongside capital raising and management. Previously, Mr. House was Head of Property at Tamesis Dual, having joined from Markel International where he worked as the Senior Property D&F Underwriter. He is ACII qualified and holds a degree in Economics from Durham University. About Fortegra For more than 45 years, Fortegra, via its subsidiaries, has underwritten risk management s

TetraMem Advances Analog In-Memory Computing with Tapeout of New 12nm AI SoC27.10.2026 09:41:00 CET | Press release

Leveraging Synopsys cloud-enabled EDA solutions to scale multi-level RRAM-based AI chip development to advanced FinFET nodes TetraMem, a Silicon Valley-based pioneer in analog in-memory computing (A-IMC), announced the successful tapeout of MLX300, the world’s first 12nm A-IMC system-on-chip (SoC) based on multi-level RRAM technology. The SoC was developed using industry-leading EDA solutions enabled through Synopsys Cloud FlexEDA, and this milestone represents a major step in bringing this architecture toward advanced-node, production-ready computing. “TetraMem’s architecture represents a fundamentally new approach to AI computing by converging memory and compute together,” said Glenn Ge, CEO and Co-founder of TetraMem. “Leveraging Synopsys EDA solutions through Synopsys Cloud have been instrumental in enabling efficient global collaboration and accelerating our path from research innovation to manufacturable silicon.” The MLX300 tapeout follows TetraMem’s recently announced MLX200/ML

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye